Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical Group's total inventories for the quarter that ended in Dec. 2025 was HK$651 Mil. Simcere Pharmaceutical Group's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was HK$638 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Simcere Pharmaceutical Group's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was HK$0.18.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Simcere Pharmaceutical Group's Days Inventory for the
six
months ended in Dec. 2025 was 144.26.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Simcere Pharmaceutical Group's Inventory Turnover for the quarter that ended in Dec. 2025 was 1.27.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Simcere Pharmaceutical Group's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.14.
Simcere Pharmaceutical Group (HKSE:02096) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Simcere Pharmaceutical Group's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Simcere Pharmaceutical Group's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Simcere Pharmaceutical Group Total Inventories Related Terms
Simcere Pharmaceutical Group Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group Total Inventories Chart
Simcere Pharmaceutical Group Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Simcere Pharmaceutical Group (HKSE:02096) has a Total Inventories of HK$651 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Simcere Pharmaceutical Group and its competitors.
Is Simcere Pharmaceutical Group's Total Inventories too high?
Simcere Pharmaceutical Group's current Total Inventories is HK$651 Mil. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Total Inventories compare to ZTS and UTHR?
Simcere Pharmaceutical Group's Total Inventories of HK$651 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Simcere Pharmaceutical Group and its competitors. Simcere Pharmaceutical Group's current Total Inventories is HK$651 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (HKSE:02096) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$10.74, compared to a current price of HK$12.73 — trading 18.5% above its estimated fair value. The current Total Inventories is HK$651 Mil. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Simcere Pharmaceutical Group (HKSE:02096), the current Total Inventories is HK$651 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (HKSE:02096) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of HK$12.73 is trading 18.5% above its estimated GF Value™ of HK$10.74.
GuruFocus considers Simcere Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for HKSE:02096:
Total Inventories: HK$651 Mil
GF Value™: HK$10.74 vs. price of HK$12.73 (18.5% above fair value)
No single metric tells the full story. See the HKSE:02096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score
Get the complete analysis for HKSE:02096
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02096 has been successfully added to your 
